Tki Primer

Dr. Stuart Goldberg, Chief, Division of Leukemia at the John Theurer Cancer Center, Hackensack University Medical Center ... Daniel George, MD, highlights strategies for managing toxicities seen with vascular endothelial growth factor-tyrosine kinase ... In our latest video, we delve into the art of resolving conflicts in the workplace using the Thomas-Kilmann Conflict Mode Instrument ... An expert in the management of differentiated thyroid cancer considers the impact of patient age when deciding therapy and the ... Luc Friboulet discusses in depth the mechanisms of resistance to tyrosine kinase inhibitors (TKIs), provides overview of current ... Dr. Stuart Goldberg, Chief, Division of Leukemia at the John Theurer Cancer Center, Hackensack University Medical Center, ...

Implications for treating patients with chronic myeloid leukemia and cytogenetic abnormalities with first- or second-generation ... A discussion about the toxicity profiles for available multikinase inhibitors for the management of NSCLC (non–small cell lung ... Overcoming Mutation Based Resistance to Tyrosine Kinase Inhibitor Therapy: Ponatinib and AP26113 Frank G. Haluska, MD, ... This video explains the Thomas Kilmann Conflict Handling Modes model - a model which helps us understand how we, and ... Difference between primary and secondary resistance attributing 50% of secondary resistance to mutations and use of ponatinib ... Insight regarding strategies for managing a patient with chronic myeloid leukemia based on his or her response to therapy with a ...

Examining the tolerability and safety of the tyrosine kinase inhibitor cabozantinib for the treatment of relapsed or refractory ... Considerations for calculating a patient with chronic myeloid leukemia's risk status and initiating therapy with a tyrosine kinase ... Lecia Sequist, MD, and Corey Langer, MD, discuss dosing strategies for mitigating side effects from tyrosine kinase inhibitors.